Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$0.52 USD

0.52
662,649

+0.01 (2.94%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.52 0.00 (0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SGMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Sangamo Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 81 278 377 641 362
Receivables 1 4 6 6 38
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 12 18 16 12 5
Total Current Assets 94 300 399 660 405
Net Property & Equipment 27 64 52 41 30
Investments & Advances 0 30 88 51 22
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 88 93 101 92
Deposits & Other Assets 18 19 17 15 11
Total Assets 165 563 722 939 638
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 15 22 10 13 18
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 32 38 32 39 14
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 52 86 92 39
Total Current Liabilities 48 112 128 144 70
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 116 173 252 88
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 41
Other Non-Current Liabilities 1 1 1 7 6
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 82 268 347 441 205
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 1 1 1
Capital Surplus 1,492 1,450 1,334 1,269 1,091
Retained Earnings -1,406 -1,149 -956 -778 -657
Other Equity -5 -8 -4 5 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 83 295 375 497 433
Total Liabilities & Shareholder's Equity 165 563 722 939 638
Total Common Equity 83 295 375 497 433
Shares Outstanding 177.30 163.80 145.60 141.40 115.90
Book Value Per Share 0.47 1.80 2.58 3.52 3.73

Fiscal Year End for Sangamo Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 81 132 143 205
Receivables NA 1 2 4 8
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 12 14 13 14
Total Current Assets NA 94 148 160 227
Net Property & Equipment NA 27 28 61 60
Investments & Advances NA 0 0 39 36
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 52
Deposits & Other Assets NA 18 16 19 18
Total Assets NA 165 220 325 441
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 15 15 15 20
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 32 32 32 28
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 1 7 10
Total Current Liabilities NA 48 48 54 58
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 8
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 82 85 91 105
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 2 2 2 2
Capital Surplus NA 1,492 1,486 1,480 1,467
Retained Earnings NA -1,406 -1,346 -1,242 -1,127
Other Equity NA -5 -7 -6 -6
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 83 135 234 336
Total Liabilities & Shareholder's Equity NA 165 220 325 441
Total Common Equity 0 83 135 234 336
Shares Outstanding 178.90 177.30 177.30 171.80 171.40
Book Value Per Share 0.00 0.47 0.76 1.36 1.96